Connective tissue diseases (CTDs) increase the risk for adverse maternal and fetal outcomes during pregnancy, with varying impacts across different CTD subtypes, according to study results published ...
Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.
A pilot trial will assess whether concentrated bone marrow aspirate can prevent inflammation and reduce postsurgery pain and ...
Hosted on MSN12m
A revolutionary patch that repairs heart damage is now realThe stem cells are turned into heart muscle cells and connective tissue cells. Cells are combined with collagen ... traits of a heart just four to eight years old. READ ALSO: Heart disease is ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) versus placebo (both in combination with ...
Merck to stop phase 3 HYPERION trial evaluating Winrevair early and move to final analysis: Rahway, New Jersey Friday, January 31, 2025, 10:00 Hrs [IST] Merck, known as MSD outsid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback